Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.

To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, Kramer B.

Respir Med. 2012 Dec;106(12):1715-21. doi: 10.1016/j.rmed.2012.09.002. Epub 2012 Oct 5.

2.

Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.

Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y; Indacaterol Asian COPD Study Investigators.

Respirology. 2012 Feb;17(2):379-89. doi: 10.1111/j.1440-1843.2011.02107.x.

PMID:
22122202
3.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
4.

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.

Respir Med. 2013 Feb;107(2):223-32. doi: 10.1016/j.rmed.2012.10.022. Epub 2012 Dec 6.

5.

Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.

Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B.

COPD. 2012 Dec;9(6):629-36. doi: 10.3109/15412555.2012.729623. Epub 2012 Sep 28.

PMID:
23020650
6.

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B; INHANCE Study Investigators.

Am J Respir Crit Care Med. 2010 Jul 15;182(2):155-62. doi: 10.1164/rccm.200910-1500OC. Epub 2010 May 12.

PMID:
20463178
7.

Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.

Mahler DA, Buhl R, Lawrence D, McBryan D.

Pulm Pharmacol Ther. 2013 Jun;26(3):348-55. doi: 10.1016/j.pupt.2013.02.006. Epub 2013 Feb 19.

PMID:
23434446
8.

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B; INTENSITY study investigators.

Eur Respir J. 2011 Oct;38(4):797-803. doi: 10.1183/09031936.00191810. Epub 2011 May 26.

9.

Indacaterol therapy in patients with COPD not receiving other maintenance treatment.

Decramer M, Rossi A, Lawrence D, McBryan D.

Respir Med. 2012 Dec;106(12):1706-14. doi: 10.1016/j.rmed.2012.08.022. Epub 2012 Sep 29. Review. Erratum in: Respir Med. 2013 Jan;107(1):160. Dosage error in article text.

10.

Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study.

Yao W, Wang C, Zhong N, Han X, Wu C, Yan X, Chen P, Yang W, Henley M, Kramer B.

Respirology. 2014 Feb;19(2):231-238. doi: 10.1111/resp.12211. Epub 2014 Jan 3.

11.

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.

Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.

Eur Respir J. 2011 Feb;37(2):273-9. doi: 10.1183/09031936.00045810. Epub 2010 Aug 6.

12.

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

Jones PW, Mahler DA, Gale R, Owen R, Kramer B.

Respir Med. 2011 Jun;105(6):892-9. doi: 10.1016/j.rmed.2011.02.013. Epub 2011 Mar 11.

13.

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.

Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.

Int J Chron Obstruct Pulmon Dis. 2014 Feb 24;9:215-28. doi: 10.2147/COPD.S51592. eCollection 2014.

14.

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.

Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.

Thorax. 2015 Apr;70(4):311-9. doi: 10.1136/thoraxjnl-2014-206345. Epub 2015 Feb 12.

15.

The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.

Kerstjens HA, Deslée G, Dahl R, Donohue JF, Young D, Lawrence D, Kornmann O.

Pulm Pharmacol Ther. 2015 Jun;32:101-8. doi: 10.1016/j.pupt.2015.02.008. Epub 2015 Mar 3.

16.

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.

Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D; INVIGORATE investigators.

Lancet Respir Med. 2013 Sep;1(7):524-33. doi: 10.1016/S2213-2600(13)70158-9. Epub 2013 Aug 21.

PMID:
24461613
17.

Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.

Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B; INTEGRAL Study Investigators.

Pulm Pharmacol Ther. 2011 Feb;24(1):162-8. doi: 10.1016/j.pupt.2010.06.005. Epub 2010 Jul 7.

PMID:
20619353
18.

Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.

Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.

Pulm Pharmacol Ther. 2007;20(6):740-9. Epub 2006 Sep 30.

PMID:
17088091
19.

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.

Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435.

PMID:
20522841
20.

Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.

Kerwin EM, Williams J.

Ther Adv Respir Dis. 2013 Feb;7(1):25-37. doi: 10.1177/1753465812470018. Epub 2013 Jan 7. Review.

PMID:
23296242

Supplemental Content

Support Center